Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Polycyclo ring system having the six-membered hetero ring as one of the cyclos (e.g., 1,3- and 1,4- benzothiazines, etc.)

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514183000 - Heterocyclic carbon compounds containing a hetero ring having chalcogen (i.e., O,S,Se or Te) or nitrogen as the only ring hetero atoms DOAI

514222200 - Hetero ring is six-membered and includes at least nitrogen and sulfur as ring members

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
514224500 At least three cyclos in the polycyclo ring system 87
514226500 One of the cyclos is a 1,2-thiazine (e.g.,1,2-benzothiazines, etc.) 68
Entries
DocumentTitleDate
20100120754IDENTIFICATION AND USE OF SMALL MOLECULES TO MODULATE TRANSCRIPTION FACTOR FUNCTION AND TO TREAT TRANSCRIPTION FACTOR ASSOCIATED DISEASES - The present invention relates to methods of identifying small molecule candidate agents capable of modulating transcription factor function such that the function/expression of a target transcription factor and/or proteins downstream of this target protein comprises the screening of small molecule libraries using in silico high throughput docking for candidate small molecules/agents that are selectively identified for their ability to target and disrupt the transcription factor-DNA interface through unique transcription factor and/or DNA descriptors that are defined within a pharmacophore, and then testing/evaluating the candidate agents identified above through one or more in vitro assays for their ability to modulate transcription factor function including expression of this target protein and/or proteins that are downstream of the target transcription factor.05-13-2010
20090192145Spiro-Imidazo Compounds - Novel heterocyclic compounds of the general formula (I) and salts, preferably pharmaceutically acceptable salts, thereof, in which R, R07-30-2009
20090192144Imidazo Compounds - The application relates to novel heterocyclic compounds of the general formula (I) and salts, preferably pharmaceutically acceptable salts, thereof in which R, R07-30-2009
200900299751,3-BENZOTHIAZINONE DERIVATIVE AND USE THEREOF - A compound represented by the formula (I) or a salt thereof: (I) wherein R01-29-2009
20120245153MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION - Compounds useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4) and use thereof.09-27-2012
20120245154SUBSTITUTED AMINOTHIAZINE DERIVATIVE - The present invention relates to an agent for treating or preventing disease induced by production, secretion and/or deposition of amyloid β protein, for example, a compound of formula (I), wherein, R09-27-2012
201202451523-(BIARYOXY)PROPIONIC ACID DERIVATIVE - A compound of the general formula (I):09-27-2012
20100093707ACID AMIDE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND PESTICIDES CONTAINING THEM - The present invention relates to an acid amid derivative of the formula (I) or a salt thereof:04-15-2010
20080280888Antibiotics Derivatives - The invention relates to antibiotic derivatives of formula I11-13-2008
20090093468Peptide Deformylase Inhibitors - Benzothiazine compounds of the general formula (I) and pharmaceutically acceptable salts or esters thereof are peptide deformylase inhibitors useful in the treatment or prevention of infections and other diseases in which peptide deformylases are involved, especially in the treatment of bacterial and parasitic infections, for example infections fully or partly caused by microorganisms belonging to 04-09-2009
20120190672FUSED AMINODIHYDROTHIAZINE DERIVATIVES - The present invention relates to a fused aminodihydrothiazine derivative of formula (I):07-26-2012
20090270375SPIRO ANTIBIOTIC DERIVATIVES - The invention relates to compounds of formula (I) wherein R10-29-2009
20090270374DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES - Bicyclic nitrogen containing compounds and their use as antibacterials.10-29-2009
20110021509PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS - Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. The compounds have the general structure:01-27-2011
20110046119THERAPEUTIC TREATMENT - A combination comprising candesartan and rosuvastatin for the prevention or treatment of atherosclerosis and for the prevention of cardiovascular events is described.02-24-2011
20090012068Condensed Imidazole Derivatives as Aldosterone Synthase Inhibitors - The application relates to novel heterocyclic compounds of the general formula (I) and salts, preferably pharmaceutically acceptable salts, thereof, in which R, R01-08-2009
20100087424TRICYCLIC NITROGEN CONTAINING HETEROCYCLES AS ANTIBACTERIAL AGENTS - Tricyclic nitrogen containing compounds and their use as antibacterials.04-08-2010
20110195961TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS - The invention relates to antibacterial compounds of formula I08-11-2011
20120028969BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF - The present invention provides compounds of formula (I);02-02-2012
20110281854MORPHOLINE COMPOUNDS - Mineralocorticoid receptor antagonists (MRa), pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetic nephropathy and hypertension in mammals, including humans.11-17-2011
20090042869SIGNAL-DEPENDENT SPLICING OF TISSUE FACTOR PRE-mRNA IN PLATELET CELLS - The invention relates to therapeutic target recognition, development, and validation of a compound capable of directly or indirectly modulating TF pre-mRNA splicing in a platelet cell and the use of a platelet TF pre-mRNA splicing modulator for the treatment of a subject suffering from, or thought to be suffering from, disordered coagulation.02-12-2009
20080306053MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH - The present invention provides screening methods for identifying modifiers of chemosensory receptors and their ligands, e.g., by determining whether a test entity is suitable to interact with one or more interacting sites within the Venus flytrap domains of the chemosensory receptors as well as modifiers capable of modulating chemosensory receptors and their ligands.12-11-2008
20080269204Compounds and Methods of Use Thereof - Benzolactam boronic acid compounds and pharmaceutical formulations are described along with methods of use thereof for inhibiting inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) in a subject in need thereof.10-30-2008
20100137290OXAZOLIDINONE ANTIBIOTIC DERIVATIVES - The invention relates to antibacterial compounds of formula I06-03-2010
201001447172-QUINOLINONE AND 2-QUINOXALINONE-DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS - The present invention relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, to their use in the treatment of bacterial infections, and to their methods of preparation.06-10-2010
20090137568Tryclic Nitrogen Containing Compounds and their Use as Antibacterials - Tricyclic nitrogen containing compounds of formula (I) and their use as antibacterials.05-28-2009
20090137567Methods for Treating Blood Disorders - Methods of treating blood disorders are described.05-28-2009
20090137566Substituted Piperdines as Renin Inhibitors - The invention relates to substituted 3,4- or higher substituted piperididine compounds, the use thereof for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; pharmaceutical formulations or products comprising said compounds, and/or a method of treatment comprising administering said compounds, a method for the manufacture of said compounds, as well as novel intermediates, starting materials and/or partial steps for their synthesis. The compounds preferably have the formula I,05-28-2009
20090275565Substituted aralkyl derivatives - The present invention relates to novel substituted aralkyl derivatives of the general formula (I) and (IIIa), their derivatives, their analogs, their tautomeric forms, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, pharmaceutical compositions containing them, use of these compounds in medicine and the intermediates involved in their preparation.11-05-2009
20090005368Ethanol or 1,2-Ethanediol Cyclohexyl Antibiotic Derivatives - The invention relates to antibiotic ethanol or 1,2-ethanediol cyclohexyl derivatives of formula (I) wherein R1 represents (C01-01-2009
20090186882CGRP RECEPTOR ANTAGONISTS - The present invention relates to CGRP receptor antagonists, pharmaceutical compositions thereof, and methods therewith for treating CGRP receptor-mediated diseases and conditions.07-23-2009
20090054417COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS - The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activation of steroid hormone nuclear receptors.02-26-2009
20100004230AZATRICYCLIC COMPOUNDS AND THEIR USE - Tricyclic nitrogen containing compounds and their use as antibacterials.01-07-2010
20090054418Antibacterial Agents - 2H-chromen-2-one derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.02-26-2009
20090093469Phenylaminopropanol Derivatives and Methods of Their Use - The present invention is directed to phenylaminopropanol derivatives of formula I:04-09-2009
20090239851Benzothiazinone Derivatives and their Use as Antibacterial Agents - The present invention relates to novel benzothiazin derivatives and their use as antibacterial agents in infectious diseases of mammals (humans and animals) caused by bacteria, especially diseases like tuberculosis (TB) and leprosy caused by mycobacteria.09-24-2009
201001521722,4-PYRIMIDINEDIAMINE COMPOUNDS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES - The present invention provides 3-hydroxyphenyl-2,4-pyrimidinediamine compounds of formula I, as well as related compositions and methods for treating a variety of autoimmune diseases.06-17-2010
20100184751HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS - Tricyclic nitrogen-containing compounds of Formula (I) or pharmaceutically acceptable salts, solvates or N-oxides thereof:07-22-2010
20120245155FUSED HETEROCYCLIC COMPOUND HAVING AMINO GROUP - The present invention provides, for example, a compound mentioned below as a medicament for treating or preventing the diseases induced by production, secretion or deposition of amyloid-βproteins.09-27-2012
20090318428HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS - Objects of the present invention are the compounds of formula I12-24-2009
20130131049COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION - Compounds of formula (I), including pharmaceutically acceptable salts thereof, are set forth herein:05-23-2013
20130131050FUSED HETEROCYCLIC COMPOUND AND APPLICATION THEREOF - The present invention provides a compound useful for the prophylaxis or treatment of eicosanoid-associated diseases such as atherosclerosis, atherothrombosis, diabetes, obesity, asthma, fever, pain, cancer, rheumatism, osteoarthritis, atopic dermatitis and the like, and having superior pharmacological action, physicochemical properties and the like.05-23-2013
20090062265Pyrrolo-Quinoxalinone Derivatives as Antibacterials - Tricyclic nitrogen containing compounds and their use as antibacterials.03-05-2009
20090069307Use of a pyridine compound for the preparation of a medicament for the treatment of skin lesions - The present invention relates to use of a pyridine compound of the following formula [I]: wherein R is a substituted pyridyl group having the following formula: R03-12-2009
20100222334Pharmaceutical Formulation of Valsartan - The present invention relates to a pharmaceutical composition in a form of suspension for oral administration comprising valsartan or its pharmaceutically acceptable salts and at least one or two or more of the components selected from glycerol or syrup or the mixture thereof, a preservative, a buffer system and a suspending/stabilizing agent. The present invention further relates to the therapeutic uses of the pharmaceutical composition.09-02-2010
20110009394TRICYCLIC NITROGEN COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS - Tricyclic nitrogen containing compounds and their use as antibacterials.01-13-2011
20110009395BACE INHIBITORS - The present invention provides BACE inhibitors of Formula I:01-13-2011
20110034445FUNGICIDE HYDROXIMOYL-HETEROCYCLES DERIVATIVES - The present invention relates to hydroximoyl-heterocycle derivatives, their process of preparation, intermediate compounds for their preparation, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions.02-10-2011
201101182416-Pyridin-3-YL-3,4-Dihydro-1H-Quinolin-2-One Derivatives and Related Compounds as Inhibitors of the Human Aldosterone Synthase CYP11B2 - The invention provides compounds of the general formula (I) which are inhibitors of the human aldosterone synthase, and also pharmaceutical compositions containing these compounds, and the use of these compounds and other heteroaryl substituted quinolinone derivatives for the treatment of hyperaldosteronism and/or disorders or diseases that are mediated by 11 β-hydroxylase (CYP11 B1).05-19-2011
20100004229Potassium Channel Inhibitors - The present invention relates to pyridin-3-yl pyridin-3-amine compounds and derivatives thereof having the structure formula (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.01-07-2010
20100056502COMPOUNDS - Tricyclic nitrogen containing compounds and their use as antibacterials.03-04-2010
20090215756FORMULATIONS CONTAINING LOSARTAN AND/OR ITS SALTS - The invention relates, in general, to new formulations and dosage units containing losartan and/or its salts (e.g., losartan potassium) that are useful for the therapeutic treatment (including prophylactic treatment) of mammals, including humans, and a process for making the same. The process generally includes (i) mixing and blending losartan potassium and a first portion of at least one of pre-gelatinized starch, microcrystalline cellulose and magnesium stearate to the mixture of step (i); (ii) compacting the mixture obtained in step (i) to form an agglomerate; (iii) breaking apart the agglomerate in order to obtain a granulate; (iv) adding lactose monohydrate and a second portion of at least one of pre-gelatinized starch, microcrystalline cellulose and magnesium stearate to the granulate and blending; and (v) tableting the granulate mixture into tablets. The process can further include coating the prepared tablets with a suitable coating material.08-27-2009
20110251185BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS - The present invention relates to a compound, useful as a mineralocorticoid receptor-modulating agent, of the following formula [I]:10-13-2011
20110039836TRICYCLIC ANTIBIOTICS - The invention relates to antibacterial compounds of formula (I)02-17-2011
20080249083NOVEL GENES RELATED TO GLUTAMINYL CYCLASE - Novel glutaminyl-peptide cyclotransferase-like proteins (QPCTLs), which are isoenzymes of glutaminyl cyclase (QC, EC 2.3.2.5), and to isolated nucleic acids coding for these isoenzymes, all of which are useful for the discovery of new therapeutic agents, for measuring cyclase activity, and for determining the inhibitory activity of compounds against these glutaminyl cyclase isoenzymes.10-09-2008
20110257165BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS - 3,4-diaryl-bicyclicpyrazole derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.10-20-2011
200900823431,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF - This invention provides a compound represented by the formula (I):03-26-2009
20080255102Phenylaminopropanol Derivatives and Methods of Their Use - The present invention is directed to phenylaminopropanol derivatives of formula I:10-16-2008
20100305110CONDENSED IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS - The application relates to novel heterocyclic compounds of the general formula (I) and salts, preferable pharmaceutically acceptable salts, thereof, in which R, R12-02-2010
201003240305-Quinoline derivatives having an anti-bacterial activity - The present invention describes novel anti-bacterial compounds of the formula (I).12-23-2010
20110136795TRICYCLIC ALKYLAMINOMETHYLOXAZOLIDINONE DERIVATIVES - The invention relates to antibacterial compounds of formula I06-09-2011
20090176772METHOD OF REVERSING LEFT VENTRICULAR REMODELING - The present invention relates to method of reversing left ventricle remodeling by combined administration of therapeutically effective amounts ranolazine and at least one co-remodeling agent, which may be an ACE inhibitor, an ARB, or a beta-blocker. The method finds utility in the treatment of heart failure. This invention also relates to pharmaceutical formulations that are suitable for such combined administration.07-09-2009
20110190278BICYCLIC HETEROCYCLIC DERIVATIVE - The present invention relates to a compound of the following formula (I) or a pharmaceutically acceptable salt thereof, being useful as a renin inhibitor.08-04-2011
201000296234-(1-AMINO-ETHYL)-CYCLOHEXYLAMINE DERIVATIVES - The invention relates to compounds of formula (I) wherein R02-04-2010
20100022520MALONYL-COA ACETYLTRANSFERASE INHIBITORS AGAINST ANTIBIOTIC RESISTANT BACTERTIA - Compounds characterized by thiolactone or thiomorpholino cores display useful antibiotic and radioprotective properties. The latter properties are believed to arise from an ability of the compounds to inhibit proteins involved in apoptosis.01-28-2010
20100331318AZATRICYCLIC ANTIBIOTIC COMPOUNDS - The invention relates to antibacterial compounds of formula I12-30-2010
20100197670AMIDINE, THIOUREA AND GUANIDINE DERIVATIVES OF 2-AMINOBENZOTHIAZOLES AND AMINOBENZOTHIAZINES FOR THEIR USE AS PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF NEURODEGENERATIVE PATHOLOGIES - Amidine, thiourea and guanidine derivatives of appropriately substituted 2-aminobenzothiazoles, 2-amino-3,1-4H-benzothiazines and 3-amino-1,4-3H-benzothiazines, as understood from formula (I), the related pharmaceutically acceptable salts and solvates thereof:08-05-2010
20110136794NOVEL PYRROLE DERIVATIVE HAVING, AS SUBSTITUENTS, UREIDO GROUP, AMINOCARBONLY GROUP AND BICYCLIC GROUP WHICH MAY HAVE SUBSTITUENT - A compound represented by the following formula (1) or a salt thereof:06-09-2011
20100286130ANTIMICROBIAL COMPOUNDS, THEIR SYNTHESIS AND THEIR USE FOR TREATMENT OF MAMMALIAN INFECTIONS - The present invention relates to compounds of Formula (I)11-11-2010
20110082132[4-(1-AMINO-EHTYL) - CYCLOHEXYL] -METHYL-AMINE AND [6-(1-AMINO-EHTYL) -TETRAHYDRO-PYRAN-3-YL] -METHYL-AMINE DERIVATIVES AS ANTIBACTERIALS - The invention relates to antibacterial compounds of formula I04-07-2011
20110071143FUSED TRIAZOLE AMINES AS P2X7 MODULATORS - Compounds of the formula I:03-24-2011
20110071142IDENTIFICATION AND USE OF SMALL MOLECULES TO MODULATE TRANSCRIPTION FACTOR FUNCTION AND TO TREAT TRANSCRIPTION FACTOR ASSOCIATED DISEASES - The present invention relates to methods of identifying small molecule candidate agents capable of modulating transcription factor function such that the function/expression of a target transcription factor and/or proteins downstream of this target protein comprises the screening of small molecule libraries using in silico high throughput docking for candidate small molecules/agents that are selectively identified for their ability to target and disrupt the transcription factor-DNA interface through unique transcription factor and/or DNA descriptors that are defined within a pharmacophore, and then testing/evaluating the candidate agents identified above through one or more in vitro assays for their ability to modulate transcription factor function including expression of this target protein and/or proteins that are downstream of the target transcription factor. The present invention also relates to various compounds described herein (e.g., a compound of Formula XI), their pharmaceutically acceptable salts and to methods of using said compounds as described herein.03-24-2011
20100081650Antimicrobial Compounds - Cyclohexane and cyclohexene derivatives and pharmaceutically acceptable derivatives thereof useful in methods of treatment of bacterial infections in mammals, particularly man.04-01-2010
20120108577COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS - The present invention relates to compounds that demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans. In particular this invention relates to compounds useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans.05-03-2012
20120108576THIAZOLE COMPOUNDS AND METHODS OF USE - The present invention provides compounds, salts and hydrates of Formula I,05-03-2012
20110092492IMIDAZO COMPOUNDS - Heterocyclic compounds of the formula (I) and salts, preferably pharmaceutically acceptable salts thereof, are provided in which R, R04-21-2011
20110082133PYRIDONE COMPOUNDS - [Problems] A useful compound which can be used as a pharmaceutical, in particular, an agent for treating peripheral arterial occlusive disease is provided.04-07-2011
20120165322RHO KINASE INHIBITORS - The present invention relates to compounds of formula (I):06-28-2012
20120122855BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY - The present invention features benzoxazines, benzothiazines, and related compounds that inhibit nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing various medical conditions.05-17-2012
20090131418SPIROAZACYCLIC COMPOUNDS AS MONOAMINE RECEPTOR MODULATORS - The present invention relates to spiroazacyclic compounds as monoamine receptor modulators; compositions comprising the same; methods of inhibiting an activity of a monoamine receptor with said compounds; methods of treating a disease condition associated with a monoamine receptor using said compounds; and methods for identifying a subject suitable for treatment using said compounds.05-21-2009
20110183968ANTIFUNGAL COMPOUNDS CONTAINING BENZOTHIAZINONE, BENZOXAZINONE OR BENZOXAZOLINONE AND PROCESS THEREOF - The present invention discloses novel compounds of the Formula (1), comprising benzothiazinone, benzoxazinone or benzoxazolinone moieties having antifungal activity, method for preparing these compounds and the use of these compounds as antifungal agents in prevention and treatment of fungal infections, and pharmaceutical preparations containing these novel compounds.07-28-2011
201202589614-AMINO-1,3-THIAZINE OR OXAZINE DERIVATIVE - The present invention provide a medicament for treating the diseases induced by production, secretion or deposition of amyloid-β proteins, for example, a compound of the following formula (I) wherein R10-11-2012
20100009976BENZOTHIAZIN-3-ONE COMPOUND AND INTERMEDIATE THEREFOR - A medicine which contains as an active ingredient a benzothiazin-3-one-compound represented by the formula (1):01-14-2010
20100009975BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY - The present invention features benzoxazines, benzothiazines, and related compounds that inhibit nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing various medical conditions.01-14-2010
20120220574METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES - The present invention provides arylpiperazine derivatives which can be advantageously used for treating schizophrenia and related psychoses such as acute manic, bipolar disorder, autistic disorder, and depression.08-30-2012
20090036433Heterocyclic Compounds, their Preparation and their Use as Antibacterials - Tricyclic nitrogen containing compounds of formula (I) and their use as antibacterials.02-05-2009
20080300240PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS - Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. The compounds have the general structure:12-04-2008
20110003798COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS - The invention provides a novel class of 2,7-naphthyridin derivatives; pharmaceutical compositions comprising such compounds and methods of using such compounds to treat o prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly Syk, ZAP70, KDR, FMS, FLT*, c-Kit, RET, TrkA, TrkB, TrkC-GR-1R, Alk, c-FMS or combinations thereof.01-06-2011
201202708642-QUINOLINONE AND 2-QUINOXALINONE-DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS - The present invention relates to compounds of Formula (I):10-25-2012
20100179134PYRIMIDINEDIAMINE KINASE INHIBITORS - The present invention provides pyrimidinediamine compounds useful for inhibiting kinase activity, including the activity of polo-like kinase 1 (PLK1). Also provided are pharmaceutical compositions comprising these compounds and methods of treating diseases associated with kinase activity, in particular enhanced PLK1 catalytic activity, such as diseases associated with abnormal cell proliferation, including neoplastic disorders.07-15-2010
201001791353-AMINO-6-(1-AMINO-ETHYL)-TETRAHYDROPYRAN DERIVATIVES - Antibacterial compounds including 3-amino-6-(1-amino-ethyl)-tetrahydropyran derivatives are provided, and methods of treatment or prevention of bacterial infection with such compounds are provided.07-15-2010
20130012501PYRIMIDINEDIAMINE KINASE INHIBITORS - Disclosed embodiments provide pyrimidinediamine compounds useful for inhibiting kinase activity, including the activity of polo-like kinase 1 (PLK1). Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating diseases associated with kinase activity, in particular enhanced PLK1 catalytic activity, such as diseases associated with abnormal cell proliferation, including neoplastic disorders.01-10-2013
20100130484NOVEL BICYCLIC SULFONAMIDE DERIVATIVES WHICH ARE L-CPT1 INHIBITORS - The invention is concerned with novel heterobicyclic derivatives of formula (I)05-27-2010
20120149691Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors - The invention provides compounds of formula I:06-14-2012
20110160193New Benzothiazinone Derivatives and Their Use as Antibacterial Agents - The present invention relates to novel benzothiazinone derivatives and their use as antibacterial agents in infectious diseases of mammals (humans and animals) caused by bacteria, especially diseases like tuberculosis (TB) and leprosy caused by mycobacteria. The present invention aims at the generation of new compounds with activity against mycobacteria as potential new tuberculosis drugs to overcome problems concerning resistance and drug intolerance. The solution of the present invention is a compound of formula I06-30-2011
20110269749TRICYCLIC CARBAMATE JAK INHIBITORS - The present disclosure relates to 2,4-pyrimidinediamines substituted with tricyclic carbamates and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, such as JAK2 or JAK3, is therapeutically useful.11-03-2011
20130203741FUSED AMINODIHYDROTHIAZINE DERIVATIVES - A compound represented by the general formula:08-08-2013
20130203740FUSED AMINODIHYDROTHIAZINE DERIVATIVES - The present invention relates to a fused aminodihydrothiazine derivative of formula (I):08-08-2013
20120094984FUSED AMINODIHYDROTHIAZINE DERIVATIVES - A compound represented by the general formula:04-19-2012

Patent applications in class Polycyclo ring system having the six-membered hetero ring as one of the cyclos (e.g., 1,3- and 1,4- benzothiazines, etc.)

Patent applications in all subclasses Polycyclo ring system having the six-membered hetero ring as one of the cyclos (e.g., 1,3- and 1,4- benzothiazines, etc.)